Back

Sodium-glucose co-transporter-2 inhibitors: prognostic benefit in real-world, elderly, comorbid HFmrEF and HFpEF patients

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Diverse pharmacological progress in heart failure Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Mrs Sandra Valdivielso

Hospital del Mar, Barcelona (Spain)

5 More presentations in this session

Presentation thumbnail
Real-world use and effectiveness of patiromer among patients with heart failure at high risk of hyperkalaemia: insights from the CARE-HK in HF registry
Doctor A. Sauer (Kansas City, US)
Abstract Slides Video
Presentation thumbnail
Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: a meta-analysis of randomized controlled trials
Doctor R. Laborante (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Diuretic resistance and the efficacy of hydrochlorothiazide in acute decompensated heart failure: a post-hoc analysis of the CLOROTIC Trial
Doctor A. Pandey (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Impact of l-arginine supplementation on quality of life in patients with heart failure: a meta-analysis of randomized controlled trials
Doctor A. Alvez (Quezon City, PH)
Abstract Slides Video
Presentation thumbnail
Serum digoxin concentrations in patients with heart failure: a post-hoc analysis of the BIOSTAT-CHF study
Mr D. Baron (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Diverse pharmacological progress in heart failure

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of SGLT2 inhibitors in heart failure: real-world evidence in geriatric patients
thumbnail
Congress Presentation
Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation
thumbnail
Congress Presentation
SGLT2i treatment at the beginning of real time exposure in a HFrEF population

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources